Amphastar Pharmaceuticals ( AMPH ) Q3 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Personalis ( PSNL ) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +14.29% and +5.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Should Value Investors Buy Amphastar Pharmaceuticals ( AMPH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down 15.4% in 4 Weeks, Here's Why Amphastar ( AMPH ) Looks Ripe for a Turnaround
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Amphastar Pharma ( NASDAQ:AMPH ) , Amneal Pharmaceuticals ( NASDAQ:AMRX )
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs.
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?
Investors need to pay close attention to AMPH stock based on the movements in the options market lately.
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Are Investors Undervaluing Amphastar Pharmaceuticals ( AMPH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar ( AMPH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 9:00 p.m. ETChief Executive Officer - Dan DischnerContinue reading ...
Amphastar Pharmaceuticals ( AMPH ) Q2 Earnings and Revenues Beat Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma ( BBIO ) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Taysha Gene Therapies, Inc. ( TSHA ) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health ( BHC ) Lags Q2 Earnings Estimates
Bausch (BHC) delivered earnings and revenue surprises of -7.22% and +2.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
What Makes Amphastar ( AMPH ) a New Buy Stock
Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Amphastar Pharmaceuticals ( AMPH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Amphastar ( AMPH ) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - DocGo ( NASDAQ:DCGO ) , Amphastar Pharma ( NASDAQ:AMPH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Richard Close downgraded DocGo Inc.
Amphastar Pharmaceuticals ( AMPH ) Tops Q1 Earnings Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 12.12% and 0.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals ( SUPN ) Q1 Earnings and Revenues Surpass Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Amphastar ( AMPH ) Stock?
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
New Strong Sell Stocks for March 24th
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds - Amphastar Pharma ( NASDAQ:AMPH )
Q4 sales rose 20% YoY to $186.5M, missing estimates of $188.81M; adjusted EPS was $0.92, below the $0.94 consensus. Primatene MIST topped $100M in annual sales, with $29M in Q4; Baqsimi posted $41.8M in Q4 sales, totaling $126.9M for 2024.
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Amphastar Pharmaceuticals ( AMPH ) Q4 Earnings and Revenues Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -4.17% and 1.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Top 2 Health Care Stocks That May Rocket Higher This Month - West Pharmaceutical Servs ( NYSE:WST )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - American Woodmark ( NASDAQ:AMWD ) , Amphastar Pharma ( NASDAQ:AMPH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst David Amsellem downgraded Amphastar Pharmaceuticals, Inc.
New Strong Sell Stocks for January 2nd
AGCO, AMPH and ASC have been added to the Zacks Rank #24 (Strong Sell) List on January 2, 2024.
New Strong Sell Stocks for December 31st
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.
Amphastar Pharmaceuticals ( AMPH ) Lags Q3 Earnings and Revenue Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -4.95% and 2.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals ( SUPN ) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma ( BBIO ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health ( BHC ) Beats Q3 Earnings and Revenue Estimates
Bausch (BHC) delivered earnings and revenue surprises of 8.74% and 3.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals ( AMPH ) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals ( AMPH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Amphastar ( AMPH ) Beat Estimates Again in Its Next Earnings Report?
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Implied Volatility Surging for Amphastar Pharmaceuticals ( AMPH ) Stock Options
Investors need to pay close attention to Amphastar Pharmaceuticals (AMPH) stock based on the movements in the options market lately.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability - Organon ( NYSE:OGN ) , Teva Pharmaceutical Indus ( NYSE:TEVA )
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
Amphastar Pharmaceuticals ( AMPH ) Tops Q2 Earnings and Revenue Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 20.51% and 6.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare ( HCA ) Beats on Q2 Earnings, Ups 2024 EPS View
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
